Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GoFast CD19 CAR T-Cell Therapy for Recurrent/Refractory B-Cell Lymphoma
NCT07670260Phase 1Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of GoFast CD19 CAR T cells in diffuse large B-cell lymphoma (DLBCL) (3 cohorts), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective Response Rate at 12 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
GoFast CD19 CAR T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07670260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670260.